tbuckley/cabot-search huggingface dataset:
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH
Authors: Stephen A Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, Madhavi Rudraraju, Dean Tai, Katy Wack, Amrik Shah, Robin Besuyen, Hilde H Steineger, David A Fraser, Arun J Sanyal
Journal: Journal of Hepatology (2025)

Via regulation of glycemic control and inflammation, free fatty receptor (FFAR)1 and 4 are potential targets for the treatment of MASH. This study tested the efficacy and safety of icosabutate, a FFAR1/FFAR4 agonist, in MASH patients. We performed a phase 2b, multicenter, 52-week, randomised, placebo-controlled trial (ICONA) testing the efficacy of icosabutate in MASH patients with F1-F3 (mild to severe) fibrosis. Patients were randomized 1:1:1 to receive once-daily, oral icosabutate 300 mg, 600 mg or placebo for 52 weeks. The primary efficacy endpoint was the proportion of patients with MASH resolution with no worsening of fibrosis in the 600 mg arm. The primary population for efficacy analysis comprised 187 patients [placebo (n=62), 300 mg icosabutate (n= 58) or 600 mg icosabutate (n=67)]. The percentage of patients with MASH resolution favoured the icosabutate 600 mg arm without reaching statistical significance (23.9% vs. 14.5%; odds ratio, 2.01; 95% confidence interval [CI], 0.8 to 5.08; P=0.13). A higher percentage of patients treated with icosabutate achieved a ≥1-stage improvement in fibrosis, with a response rate of 29.3% in the 300 mg arm (odds ratio, 2.89; 95% CI, 1.09 to 7.70))and 23.9% in the 600 mg arm (odds ratio, 2.4; 95% CI, 0.90 to 6.37)) vs. 11.3% in the placebo arm. An improvement in fibrosis was observed using AI-assisted digital pathology. Marked decreases in biomarkers of liver damage were observed. Icosabutate was generally safe and well tolerated, with mild to moderate TEAEs and no reports of drug induced liver injury. Although the primary endpoint was not met, treatment with icosabutate demonstrated encouraging fibrosis (as measured by both conventional and AI-assisted digital pathology) and non-invasive biomarker data, supporting further development in MASH patients. NCT04052516 IMPACT AND IMPLICATIONS: • With expression on multiple cells types regulating both glycemic control and liver inflammation, targeting free fatty acid receptors 1 and 4 could offer an attractive approach for the treatment of both fibrosing MASH and it's comorbidities.• Although treatment of F1-F3 MASH patients with oral icosabutate (a FFAR1/FFAR4 agonist) did not meet the pre-defined primary endpoint (MASH resolution without worsening of fibrosis), the overall dataset (including AI-assisted digital pathology) suggest an improvement in fibrosis in treated patients.• Improvements in multiple biomarkers of liver damage, inflammation and glycemic control were observed in response to therapy.• Icosabutate was generally safe and well-tolerated, and the overall data support further testing of icosabutate in MASH patients, in particular those with more advanced disease (F2-F3 fibrosis) and type 2 diabetes.
Anti-obesity pharmacotherapy for patients with genetic obesity due to defects in the leptin-melanocortin pathway
Authors: Mila S Welling, Elisabeth F C van Rossum, Erica L T van den Akker
Journal: Endocrine Reviews (2025)

Abstract Lifestyle interventions are the cornerstone of obesity treatment. However, insufficient long-term effects are observed in patients with genetic obesity disorders, as their hyperphagia remains untreated. Hence, patients with genetic obesity often require additional pharmacotherapy to effectively manage and treat their hyperphagia and obesity. Recent advancements in anti-obesity pharmacotherapy have expanded the range of available anti-obesity medications (AOM). This includes the targeted AOM setmelanotide, approved for specific genetic obesity disorders, as well as non-targeted AOMs such as naltrexone-bupropion and glucagon-like peptide-1 analogues. Targeted AOMs have demonstrated significant weight loss, reduced obesity-related comorbidities, and improved hyperphagia and quality of life in patients with genetic obesity. Small observational studies have shown that similar benefits from non-targeted AOMs or off-label pharmacotherapies can be achieved in patients with specific genetic obesity disorders, compared to common multifactorial obesity. In the future, novel and innovative pharmacotherapeutical options, including combination therapies and possibly gene therapy, will emerge, offering promising effects on body weight, hyperphagia, and, most importantly, quality of life for patients with a variety of genetic obesity disorders.
CORRELATION OF SERUM LEVELS OF IgE AND EOSINOPHILIA WITH THE SEVERITY OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS
Authors: Angelica Noriega, Camilla Pereira, Juliana Primon, Thalita Picciani, LARISSA MACHADO, Tayna Padilha, MAITE SAAB, GUILHERME MARTINS, GABRIELA SPESSATTO, DEBORA CHONG-SILVA, Laura Araujo, Herberto Chong Neto, Nelson Rosario
Journal: Journal of Allergy and Clinical Immunology (2025)
Enumeration of Sputum CD8+ T cells and ILC2 in Severe Asthma Exacerbations
Authors: Nahal Emami Fard, Xiaotian Ju, Chynna Huang, Lucy Chen, Paul O, Imran Satia, Katherine Radford, Manali Mukherjee, Terence Ho, Parameswaran Nair, Roma Sehmi
Journal: Journal of Allergy and Clinical Immunology (2025)
Health care resource utilization in pediatric and adult patients with IgE-mediated food allergy: Results from the ASSESS FA study
Authors: Ruchi Gupta, Margitta Worm, Tarek Mnif, Suzanne Reed, Stefani Dritsa, Perrine Le Calve, Alissar Moussallem, Paolo Tassinari, Jessica Marvel, Alessandro Fiocchi
Journal: Journal of Allergy and Clinical Immunology (2025)
Polygenic asthma risk is mediated through T2, wound-healing, and asthma medication response transcriptomic pathways in African-ancestry individuals
Authors: Rakesh Natarajan, Brooke Szczesny, Meher Preethi Boorgula, Sameer Chavan, Monica Campbell, Randi Johnson, Harold Watson, Nadia Hansel, Christopher Olopade, Charles Rotimi, R Clive Landis, Camilla Figueiredo, Carole Ober, Margaret Taub, Kathleen Barnes, Genevieve Wojcik, Rasika Mathias
Journal: Journal of Allergy and Clinical Immunology (2025)
The epidemiology of chronic urticaria in Cape Town, South Africa: a review of two tertiary referral centers
Authors: Cascia Day, Mimi Deetlefs, Yejin Jang, Sicelo Ntuli, Balican Hlungwani, Susanna Kannenberg, Ndapewa Ambondo, Willem Visser, Thuraya Isaacs, Rannakoe Lehloenya, Jonny Peter
Journal: Journal of Allergy and Clinical Immunology (2025)
Prediction of oral food challenge outcome using machine learning methods
Authors: Tomoyuki Arima, Taku Hirose, Junna Oba, Tetsuo Ishikawa, Yosuke Ichigi, Miyu Ono, Mayuko Gondo, Kazuya Sugita, Takahiro Nishida, Rei Kanai, Fumiko Iwai, Yu Kuwabara, Mizuho Nagao, Etsuhisa Takahashi, Hiroshi Kido, Kazuhiro Sakurada, Takao Fujisawa
Journal: Journal of Allergy and Clinical Immunology (2025)
Utilization of Complementary and Alternative Medicine Among Children with Food Allergy in the FORWARD Cohort
Authors: Gary Soffer, Lucy Bilaver, Jialing Jiang, Xueqing Zhou, Christopher Warren, Araceli Romero Jimenez, Melissa Engel, Hemant Sharma, Ruchi Gupta
Journal: Journal of Allergy and Clinical Immunology (2025)
Synergistic downregulation of T cell-dependent steroid-resistant asthma model by costimulatory signal blockade and kinase inhibitors
Authors: Akio Mori, Satoshi Kouyama, Akemi Ohtomo-Abe, Yoshihiro Furukawa, Ryo Sato, Takashi Katsuno, Yuichiro Kawasaki, Yuto Nakamura, Yosuke Kamide, Kiyoshi Sekiya, Takayuki Ohtomo, Osamu Kaminuma
Journal: Journal of Allergy and Clinical Immunology (2025)
Nocturnal Pediatric Asthma Exacerbations are Associated with Distinct Epithelial Circadian, Neuronal, and Inflammatory Networks
Authors: Randall Combs, Kieran Phelan, Dan Spagna, Seth Jenkins, Brittany Grashel, Jeff Burkle, Jocelyn Biagini, Maninder Kalra, Kristie Ross, Karen McCoy, Kim Dill-McFarland, Tesfaye Mersha, Matthew Altman, Gurjit Khurana Hershey
Journal: Journal of Allergy and Clinical Immunology (2025)
Rilzabrutinib Improves Chronic Spontaneous Urticaria in Patients With and Without Allergic Comorbidities: A Subgroup Analysis From the RILECSU Study
Authors: Jordan Talia, Saini Sarbjit, Chih-Hung Lee, Iris Sun, Vincent Mikol, Leda Mannet, Jessica Gereige
Journal: Journal of Allergy and Clinical Immunology (2025)
Achieving asthma remission with extrafine beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB) pMDI in adults with moderate-to-severe asthma: A post-hoc analysis of the TRIMARAN and TRIGGER Studies
Authors: Mohammed Hanslot, Guy Brusselle, Alberto Papi, Johann Virchow, G. Canonica, David Singh, Laura Franzini, Andrea Vele, George Georges
Journal: Journal of Allergy and Clinical Immunology (2025)
IRL201104, A Novel Immunomodulatory Peptide, Drives An Increase In T And B Regulatory Cell Phenotypes And Shows Long Lasting Efficacy Through Different Routes Of Administration In A Mouse Model Of Allergic Inflammation
Authors: Jorge De Alba, Lara Ravanetti, Emily Offer, Chris Thornton, Valerie Corrigall, Paul Eggleton, Roly Foulkes
Journal: Journal of Allergy and Clinical Immunology (2025)
Associations Between Food Allergy and Adverse Event Outcomes Among Medicaid-Enrolled Children With Asthma
Authors: Megan Hunter Patt, Melanie Boyd, Arina Eyimina, Clare Brown, Erhan Ararat, Mandana Rezaeiahari, J Mick Tilford, Tamara Perry, Stacie Jones, Akilah Jefferson
Journal: Journal of Allergy and Clinical Immunology (2025)
The Bruton's Tyrosine Kinase Inhibitor Acalabrutinib Synergistically Reduces Mortality with Epinephrine When Used as a Rescue Treatment for Anaphylaxis in Humanized Mice
Authors: Betania Arce, Natalia Vilela, Kristina Sokol, Derek Croote, Melanie Dispenza
Journal: Journal of Allergy and Clinical Immunology (2025)
Mepolizumab Improves and Sustains Clinical Benefits in Patients With Severe Asthma, Independent of Blood Eosinophil Count at Baseline: Real-World Analysis of REALITI-A Results at 2 Years
Authors: Mark Liu, Jason Lee, Steven Gould, Stephen Noorduyn, Lingjiao Zhang, Rafael Alfonso-Cristancho, Peter Howarth
Journal: Journal of Allergy and Clinical Immunology (2025)
Associations between genetic ancestry and serum Immunoglobulin E trajectory, allergen-specific IgE sensitization, and asthma at 10 years among Black children in the WHEALS birth cohort
Authors: Kelsey Finkel, Chun-Hui Lin, Alexandra Sitarik, Haejin Kim, Amy Eapen, Alan Baptist, Albert Levin, Andrea Cassidy-Bushrow, Christine Johnson, Edward Zoratti
Journal: Journal of Allergy and Clinical Immunology (2025)
Variations in Date Palm (Phoenix dactylifera L) pollen in Qatar pollen forecast: a need for assessing allergy risks in the desert regions during natural and artificial pollination season
Authors: Maryam Al-Nesf Al-Mansouri, Yasmin Elkhatib, Dana Deyab, Sami Aqel, Hassan Mobayed, Maria Del Mar Trigo
Journal: Journal of Allergy and Clinical Immunology (2025)
Evaluation of the performance of biologics in severe T2 asthma in real life
Authors: Dulce Sánchez- Torralvo, Almudena Testera Montes, Guillermo Bentabol-Ramos, Marta Ferrer, Joan Bartra, Maria Torres Jaen, Carmen Rondon Segovia, Ibon Eguiluz
Journal: Journal of Allergy and Clinical Immunology (2025)
Asthma Medication Use Before and After an Asthma Exacerbation: a US Claims-based Study
Authors: Bill Cook, Mina Khezrian, Tim Harrison, Tham Le, Tianshi Wu, Kirsty Rhodes, Jonatan Hedberg, Nicole Zubizarreta, Joshua Enxing, Trung Tran
Journal: Journal of Allergy and Clinical Immunology (2025)
Correlation of Blood CD8+ CD60+, CD4+ CD25+ and CD1d+ Cells with Total Serum IgE Levels in Adults with Asthma and Rhinoconjunctivitis
Authors: Racha Abi Melhem, Tamar Smith-Norowitz, Sairaman Nagarajan, Yecheskel Gold, Rauno Joks
Journal: Journal of Allergy and Clinical Immunology (2025)
Greater Odds of Clinical Remission With Mepolizumab Versus Placebo in Severe Asthma: A 24-Week Individual Patient Data Meta-Analysis of RCTs
Authors: Steven Gould, Andréanne Côté, Njira Lugogo, Ruchong Chen, Stephen Weng, Brandon Butcher, Anna Pence, Stephen Noorduyn, Peter Howarth
Journal: Journal of Allergy and Clinical Immunology (2025)
Interactions Between Polygenic Pleiotropy and Air Pollution in the Pathogenesis of Atopic Dermatitis
Authors: Yun-wen Chen, I-Chieh Chen, Hui-Wen Yang, Kuo-Tung Tang, Hsin-Hua Chen, Wen-Nan Huang, Yi-hsing Chen, Yi-Ming Chen
Journal: Journal of Allergy and Clinical Immunology (2025)
Impact of Sleep Disorders on Quality of Life and Disease Control in Chronic Urticaria Patients: A Cross-Sectional Analysis
Authors: Ivan Cherrez Ojeda, Mariam Ali Yousuf Al-Nesf, Tayseer Ibrahim, Sherin Rahim Thalapp, Luis Felipe Ensina, Alex Lacerda, Roberta Criado, Nelson Muñoz, Daniela Muñoz, Juan Muñoz, Alicja Kasperska-Zajac, Anna Zalewska-Janowska, Dorota Krasowska, Joanna Bartosiński, Marta Kolacinska-Flont, Izabela Kupryś-Lipińska, Marcin Kurowski, Katarzyna Tomaszewska, Zenon Karol Brzoza, Daria Fomina, Nikolái Strelyaev, Allenova Anastasiia Anastasiia, Andrey Allenov, Inna Danilycheva, Elena Latysheva, Raisa Meshkova, Ana Gimenez-Arnau, David Pesqué, Kanokvalai Kulthanan, Noldtawat Viriyaskultorn, Phuwakorn Saengthong-aram, Deniz ILGUN. GUREL, Özlem Su-Küçük, Emek Kocatürk, Ümit Murat Şahiner., Maryam Khoshkhui Khoshkhui, Esen Özkaya, Petra Staubach-Renz, Yasemin Erdem, Thomas Roth, Ömer Mangır, Luis Escalante, Deniz Ozceker, Iman Nasr, Leonie Herzog
Journal: Journal of Allergy and Clinical Immunology (2025)
Mepolizumab Improves and Sustains Clinical Benefits in Patients With Severe Asthma, Independent of IgE and FeNO at Baseline: Real-World Analysis of REALITI-A Results at 2 Years
Authors: Jason Lee, Mark Liu, Steven Gould, Stephen Noorduyn, Lingjiao Zhang, Rafael Alfonso-Cristancho, Peter Howarth
Journal: Journal of Allergy and Clinical Immunology (2025)
Bioactive mediator profile of mepolizumab-treated eosinophilic granulomatosis with polyangiitis
Authors: Yosuke Kamide, Kyuto Sonehara, Kiyoshi Sekiya, Shigeharu Ueki, Yuto Nakamura, Yukinori Okada, Masami Taniguchi
Journal: Journal of Allergy and Clinical Immunology (2025)
COVID-19 and HAE Flares: Hereditary Angioedema Attacks with COVID-19 Vaccination
Authors: Tess Robart, Gina Lacuesta, Stephen Betschel, Rozita Borici-Mazi, Victoria Cook, Chrystyna Kalicinsky, Amin Kanani, Paul Keith, Susan Waserman
Journal: Journal of Allergy and Clinical Immunology (2025)
A healthy city? Urban Aerobiology, Vegetation Dynamics and Intensity of Use in La Puntilla, Ecuador
Authors: Ivan Cherrez Ojeda, Jean Bousquet, Daniela Hidalgo Molina, Oscar Calderon LLosa, Juan Calderon, Anna Bedbrook, Karen Bohorquez Maldonado, Gabriela Rodas-Valero, Ana Ochoa-Brito, Andres Espinoza Maticurena, Laura Barrionuevo, German Ramon, Karla Robles-velasco
Journal: Journal of Allergy and Clinical Immunology (2025)
Efficacy And Safety Of Tezepelumab In Adults With Severe, Uncontrolled Asthma In Asia: Results From The Regional, Phase 3 DIRECTION Study
Authors: Yang Yan, Lihong Wang, Kewu Huang, Wei Tang, Eli Berame, Hae-sim Park, Gillian Hunter, Wei Jiang, Chengyi (Chloe) Wu, Chiju (Wendy) Min, Katarzyna Domek-Łopacinska, Harbans Lal, Nestor Molfino, Sandhia Ponnarambil, Nanshan Zhong
Journal: Journal of Allergy and Clinical Immunology (2025)
Egg and Milk Allergy vs. Avoidance: Impact on Growth in a Pediatric Food Allergy Cohort
Authors: Ozge Nur Aktas, Yoon Hee Kim, Megan Grieco, Allyson Mateja, Aristides Hatzimemos, Diana Nichols-vinueza, Erica Brittain, Pamela Guerrerio
Journal: Journal of Allergy and Clinical Immunology (2025)
Pathways to Crime and Antisocial Behavior: A Critical Analysis of Psychological Research and a Call for Broader Ecological Perspectives
Authors: Edelyn Verona, Bryanna Fox
Journal: Annual Review of Clinical Psychology (2025)

The United States has one of the highest rates of correctional supervision among all nations in the world, reflecting the disproportionate incarceration of racial minorities and economically disadvantaged groups. Scholars have emphasized the role of structural factors and governmental policies in long-term shifts in crime and incarceration. However, much of the psychological research on crime and antisocial behaviors has not deeply considered this broader context, focusing mostly on individual and proximal environmental risk factors. This article presents a novel synthesis of large cross-disciplinary literatures that have not been previously integrated. After a brief summary of dominant themes in psychological research on the topic, we review the strong evidence, primarily from fields outside of psychology, for structural forces that explain pathways into criminal justice involvement, independent of individual-level explanations. A broader ecological framework is outlined to help unconfound individual and structural influences, with the hope of motivating policy change that is evidence-based and equitable.
Youth with Behavioral Health Symptoms in the Juvenile Legal System: From Assessment of Needs to Interventions to Scalability
Authors: Kathleen Kemp, Kaitlin Sheerin, Casey Pederson, Miyah Grant, Crosby Modrowski, Anthony Spirito
Journal: Annual Review of Clinical Psychology (2025)

This article provides an overview of the current state of assessment and clinical intervention approaches for youth with juvenile legal system (JLS) involvement. The review includes ( a ) a brief overview of characteristics of youth with JLS involvement; ( b ) current screening and assessment frameworks within the JLS that identify treatment needs; ( c ) an overview of effective clinical interventions for common behavioral health concerns among youth with JLS involvement, including information about tailoring interventions to address the multiple intersecting identities (e.g., race, ethnicity, gender identity, sexual orientation) of youth within the JLS; and ( d ) an overview of implementation models and scalability of interventions.
Movement Toward Dimensional Symptom Models of Comorbid Obsessive–Compulsive Disorder and Eating Disorders
Authors: Cheri A. Levinson, Avantika Kapadia, Luis E. Sandoval-Araujo, Irina A. Vanzhula, Karyne Machry
Journal: Annual Review of Clinical Psychology (2025)

Obsessive–compulsive disorder (OCD) and eating disorders (EDs) are highly comorbid. Despite the high comorbidity, there is little understanding of why these disorders coexist and even less research on how to best treat this co-occurrence. In this article, we review the literature on comorbid OCD-ED and discuss potential underlying shared mechanisms, including anxiety/avoidance, perfectionism, intolerance of uncertainty, habit formation, disgust, shame and guilt, rumination, metacognitive beliefs, and shared biological characteristics. We then discuss prior models of OCD-ED comorbidity and shift the perspective from latent or categorical models to dimensional symptom models (e.g., network models). We describe how dimensional symptom models could advance the conceptualization, treatment, and prevention of comorbid OCD-ED. Next, we discuss how idiographic (one-person) symptom models could advance personalized treatment and provide a treatment example. Finally, we discuss future research needed to advance the field and improve treatment outcomes.
Recombinant protein HR212 targeting heptad repeat 2 domain in spike protein S2 subunit elicits broad‐spectrum neutralizing antibodies against SARS‐CoV‐2 and its variants
Authors: Ying Lu, An‐Qi Li, Fan Shen, Wen‐Qiang He, Shu‐Heng Yu, Yan‐Bo Zhao, Xiao‐Li Feng, Ming‐Hua Li, Songying Ouyang, Yong‐Tang Zheng, Wei Pang
Journal: MedComm (2025)

Abstract SARS‐CoV‐2 variants are under continuous emergence carry numerous mutations within S1 subunit in spike protein and have escaped neutralization through many currently used vaccines and antibodies. The development of next‐generation vaccines is a continuing and long‐term need. In our prior research, the recombinant protein vaccine HR121 targeting the heptad repeat (HR) 1 domain of S2 subunit was constructed, which could evoke highly broad‐spectrum neutralizing antibodies in vivo and confer efficient protective effect on several SARS‐CoV‐2 variants within multiple animal models. Compared with HR1, HR2 domain shows a more conservative degree within SARS‐CoV‐2 and related coronaviruses. Here, we designed a recombinant protein HR212 consisting of HR2–linker1–HR1–linker2–HR2. HR212 showed a high affinity with HR1 and was functionally analogous to HR2 within fusion intermediate in S2 subunit. Immunizing rabbits using HR212‐mediated high nAbs for 28 pseudotyped SARS‐CoV‐2 variants, like currently circulating variants, such as BA.2.86 and JN.1. Transfer of rabbit anti‐HR212 sera or immunization with HR212 offered efficient protective effect on SARS‐CoV‐2 ancestral strain and Omicron BA.2 variant infections of Syrian golden hamsters. According to our results, HR2 domain of S2 subunit is the novel target that can be used to develop broad‐spectrum vaccines to resist SARS‐CoV‐2 variants.
Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 <scp>XTEND</scp>‐1 Study
Authors: Angela C. Weyand, Sandrine Meunier, Nobuaki Suzuki, Linda Bystrická, Graham Neill, Lydia Abad‐Franch, Annemieke Willemze, Alberto Tosetto
Journal: American Journal of Hematology (2025)

ABSTRACT Despite therapeutic advances, people with hemophilia experience bleeds. These may be life‐threatening, result in permanent joint damage, chronic pain, difficulties with mobility/daily activities, and impact quality of life. In the XTEND‐1 study (NCT04161495), once‐weekly efanesoctocog alfa (50 IU/kg) prophylaxis provided highly effective bleed prevention and high‐sustained factor levels for most of the week and was well‐tolerated. We report post hoc analysis of bleeding episodes and their treatment in previously treated patients (≥ 12 years old). Participants received 50 IU/kg efanesoctocog alfa either as once‐weekly prophylaxis (Arm A) or on‐demand followed by once‐weekly prophylaxis (Arm B) in XTEND‐1. Endpoints included treatment of bleeding episodes and response to treatment. During XTEND‐1, 422 bleeding episodes were reported among 159 participants; 362 were treated. Most treated bleeding episodes (74%; n = 268) occurred during the Arm B on‐demand period, of which 197 (74%) were spontaneous. Seventy‐five participants had no bleeding episodes in Arm A; all in Arm B had ≥ 1 bleeding episode while on‐demand. Most participants ( n = 107, 81%) had zero treated spontaneous bleeding episodes and rates of treated bleeding episodes in Arm A (prophylaxis) were low (median [interquartile range] overall ABR: 0.00 [0.00–1.04]). A single injection was sufficient to resolve 97% (350/362) of treated bleeding episodes, no bleeding episodes required &gt; 3 injections, and responses to 95% of evaluable injections were rated excellent/good. Median total dose was 50.9 IU/kg per bleeding episode. Results of this analysis further demonstrated that once‐weekly efanesoctocog alfa provides highly effective bleed protection and treatment of bleeding episodes in participants with severe hemophilia A. Trial Registration: NCT04161495
Neurobiological Role and Therapeutic Potential of Exercise-Induced Irisin in Alzheimer's Disease Management
Authors: Nandini Ratne, Sakshi Jari, Manasi Tadas, Raj Katariya, Mayur Kale, Nandkishor Kotagale, Dilip Madia, Milind Umekar, Brijesh Taksande
Journal: Ageing Research Reviews (2025)